Oligonucleotides are becoming the newly validated drug platform, creating access to over 30,000 new intracellular pharmaceutical targets. Efficient delivery of the technology remains elusive and will most likely require a multi-approach based solution. This text is evaluates what we have learned over the last 25 years, what works and what does not. It also addresses the question of where the field is going in the future.
"synopsis" may belong to another edition of this title.
(No Available Copies)
If you know the book but cannot find it on AbeBooks, we can automatically search for it on your behalf as new inventory is added. If it is added to AbeBooks by one of our member booksellers, we will notify you!Create a Want